For higher doses, use a more concentrated mix (less water per vial) or a larger vial so the draw stays under 1 mL splitting a dose across two injections adds error and injection-site burden
Data from nationwide registers from Sweden, Denmark and Norway showed that patients initiating SGLT-2i were less likely to develop renal adverse events, such as RRT, hospitalization, or death for renal causes, compared to GLP-1RA users [37]
Rasmussen CB, Lindenberg S
The honest answer is that it's a coherent hypothesis with a sizeable body of anecdotal reporting behind it, not an established phenomenon
They are a clinically established treatment for B12 deficiency
doi: 10.1155/2017/2549491 204 NordioMBascianiS